FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3199543339> ?p ?o ?g. }

• W3199543339 endingPage "1438" @default.
• W3199543339 startingPage "1438" @default.
• W3199543339 abstract "There is an increasing interest in controlled release systems for local therapy in the treatment of human and equine joint diseases, aiming for optimal intra-articular concentrations with no systemic side effects. In this study, the intra-articular tolerability and suitability for local and sustained release of tacrolimus (FK506) from monospheres composed of [PDLA-PEG1000]-b-PLLA multiblock copolymers were investigated. Unloaded and tacrolimus-loaded (18.4 mg tacrolimus/joint) monospheres were injected into the joints of six healthy horses, with saline and hyaluronic acid (HA) in the contralateral joints as controls. Blood and synovial fluid were analysed for the tacrolimus concentration and biomarkers for inflammation and cartilage metabolism. After an initial burst release, sustained intra-articular tacrolimus concentrations (>20 ng/mL) were observed during the 42 days follow-up. Whole-blood tacrolimus levels were below the detectable level (<0.5 ng/mL). A transient inflammatory reaction was observed for all substances, evidenced by increases of the synovial fluid white blood cell count and total protein. Prostaglandin and glycosaminoglycan release were increased in joints injected with unloaded monospheres, which was mitigated by tacrolimus. Both tacrolimus-loaded monospheres and HA transiently increased the concentration of collagen II cleavage products (C2C). A histologic evaluation of the joints at the endpoint showed no pathological changes in any of the conditions. Together, these results indicate the good biocompatibility of intra-articular applied tacrolimus-loaded monospheres combined with prolonged local drug release while minimising the risk of systemic side effects. Further evaluation in a clinical setting is needed to determine if tacrolimus-loaded monospheres can be beneficial in the treatment of inflammatory joint diseases in humans and animals." @default.
• W3199543339 created "2021-09-27" @default.
• W3199543339 creator A5003556789 @default.
• W3199543339 creator A5009811033 @default.
• W3199543339 creator A5044835238 @default.
• W3199543339 creator A5061969768 @default.
• W3199543339 creator A5070135934 @default.
• W3199543339 creator A5073803993 @default.
• W3199543339 creator A5077676327 @default.
• W3199543339 creator A5085668983 @default.
• W3199543339 creator A5088319900 @default.
• W3199543339 creator A5088667969 @default.
• W3199543339 date "2021-09-10" @default.
• W3199543339 modified "2023-09-26" @default.
• W3199543339 title "Sustained Intra-Articular Release and Biocompatibility of Tacrolimus (FK506) Loaded Monospheres Composed of [PDLA-PEG1000]-b-[PLLA] Multi-Block Copolymers in Healthy Horse Joints" @default.
• W3199543339 cites W1932410428 @default.
• W3199543339 cites W1968479070 @default.
• W3199543339 cites W1974739876 @default.
• W3199543339 cites W1975916494 @default.
• W3199543339 cites W1977683960 @default.
• W3199543339 cites W1981005966 @default.
• W3199543339 cites W1981351737 @default.
• W3199543339 cites W1987754032 @default.
• W3199543339 cites W1989125541 @default.
• W3199543339 cites W1993523958 @default.
• W3199543339 cites W2001646063 @default.
• W3199543339 cites W2006371414 @default.
• W3199543339 cites W2024218300 @default.
• W3199543339 cites W2030844560 @default.
• W3199543339 cites W2034031125 @default.
• W3199543339 cites W2034742209 @default.
• W3199543339 cites W2034759695 @default.
• W3199543339 cites W2035276049 @default.
• W3199543339 cites W2043575440 @default.
• W3199543339 cites W2045100331 @default.
• W3199543339 cites W2054711890 @default.
• W3199543339 cites W2057800397 @default.
• W3199543339 cites W2064647582 @default.
• W3199543339 cites W2085111729 @default.
• W3199543339 cites W2086954987 @default.
• W3199543339 cites W2088942316 @default.
• W3199543339 cites W2095809391 @default.
• W3199543339 cites W2097776729 @default.
• W3199543339 cites W2102804688 @default.
• W3199543339 cites W2103495251 @default.
• W3199543339 cites W2107653734 @default.
• W3199543339 cites W2112073300 @default.
• W3199543339 cites W2128149258 @default.
• W3199543339 cites W2145650199 @default.
• W3199543339 cites W2152284520 @default.
• W3199543339 cites W2155402987 @default.
• W3199543339 cites W2163140311 @default.
• W3199543339 cites W2329573625 @default.
• W3199543339 cites W2388992917 @default.
• W3199543339 cites W2548910812 @default.
• W3199543339 cites W2551034188 @default.
• W3199543339 cites W2607890813 @default.
• W3199543339 cites W2618359448 @default.
• W3199543339 cites W2713033089 @default.
• W3199543339 cites W2770586957 @default.
• W3199543339 cites W2801332313 @default.
• W3199543339 cites W2801943384 @default.
• W3199543339 cites W2805582518 @default.
• W3199543339 cites W283469004 @default.
• W3199543339 cites W2901820439 @default.
• W3199543339 cites W2982369364 @default.
• W3199543339 cites W3135546643 @default.
• W3199543339 cites W4232900352 @default.
• W3199543339 cites W4241551895 @default.
• W3199543339 doi "https://doi.org/10.3390/pharmaceutics13091438" @default.
• W3199543339 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8465142" @default.
• W3199543339 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34575514" @default.
• W3199543339 hasPublicationYear "2021" @default.
• W3199543339 type Work @default.
• W3199543339 sameAs 3199543339 @default.
• W3199543339 citedByCount "1" @default.
• W3199543339 countsByYear W31995433392023 @default.
• W3199543339 crossrefType "journal-article" @default.
• W3199543339 hasAuthorship W3199543339A5003556789 @default.
• W3199543339 hasAuthorship W3199543339A5009811033 @default.
• W3199543339 hasAuthorship W3199543339A5044835238 @default.
• W3199543339 hasAuthorship W3199543339A5061969768 @default.
• W3199543339 hasAuthorship W3199543339A5070135934 @default.
• W3199543339 hasAuthorship W3199543339A5073803993 @default.
• W3199543339 hasAuthorship W3199543339A5077676327 @default.
• W3199543339 hasAuthorship W3199543339A5085668983 @default.
• W3199543339 hasAuthorship W3199543339A5088319900 @default.
• W3199543339 hasAuthorship W3199543339A5088667969 @default.
• W3199543339 hasBestOaLocation W31995433391 @default.
• W3199543339 hasConcept C105702510 @default.
• W3199543339 hasConcept C141071460 @default.
• W3199543339 hasConcept C142724271 @default.
• W3199543339 hasConcept C1621761 @default.
• W3199543339 hasConcept C178790620 @default.
• W3199543339 hasConcept C185592680 @default.
• W3199543339 hasConcept C197934379 @default.
• W3199543339 hasConcept C204787440 @default.
• W3199543339 hasConcept C2776164576 @default.

• next